Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaohong Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Gang Wu(Hubei University of Chinese Medicine), Junling Li(Tianjin Academy of Agricultural Sciences), Kaican Cai(Nanfang Hospital), Qisen Guo(Shandong Tumor Hospital), Ning Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Liu(Hebei Medical University), Guoqing Liao(307th Hospital of Chinese People’s Liberation Army), Shucai Zhang(Northeastern University), Xiuwen Wang(Second Hospital of Shandong University), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiwei Liu(Mongolian University of Science and Technology), Ping Yu(Sichuan Cancer Hospital), Yunpeng Liu(Shenyang Institute of Automation), Ligong Nie(Peking University), Shujun Yang(Henan Cancer Hospital), Liangan Chen(Wenzhou Medical University)
Cited by 206
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k